Company Profile
Star Sports Medicine Co., Ltd. is a China-based manufacturer of sports medicine implants and arthroscopic equipment, headquartered in Beijing, China. Founded in 2017 by Ms. Nie Wei, Mr. Dong Wenxing, and Mr. Chen Hao, the company operates as a publicly listed entity on the Hong Kong Stock Exchange (HKEX: 1609) following its listing on May 5, 2026, serving global sports medicine and orthopedic markets across China, Europe, Southeast Asia, the Middle East, and Latin America with approximately 373 employees.
Core Products ＆ Technologies
Sports Medicine Implants
• Suture Anchors: Titanium, PEEK, and all-suture anchors for soft tissue fixation to bone in shoulder, knee, ankle, hip, and wrist joints
• Interference Screws ＆ Sheath Fixation Systems: PEEK and bioabsorbable screws for ACL/PCL reconstruction and soft tissue-to-bone fixation
• Suture Buttons ＆ Ultra High-Strength Sutures: Titanium alloy plate and UHMWPE loop systems for ligament reconstruction; UHMWPE sutures for tendon repair
• Meniscus Repair Systems: All-inside and inside-out meniscus repair devices for tear fixation
Arthroscopic Equipment ＆ Consumables
• Arthroscopic Shaver Systems: Powered handheld shaver systems with interchangeable blades for minimally invasive joint debridement
• Arthroscopic Tower: Integrated endoscopic video image system for arthroscopic visualization
• RF Electrodes: Radiofrequency probes for soft tissue ablation and hemostasis during arthroscopy
• Surgical Instruments: Cannulas, suture passers, and specialized tools for arthroscopic procedures
Regenerative ＆ Intelligent Platforms
• Regenerative Repair Products: Tissue-engineered scaffolds and PRP preparation kits for joint soft tissue regeneration
• Intelligent Medicine Platform: Emerging AI-driven technologies for surgical robotics and sports medicine prescription systems
Market Position ＆ Certifications
Star Sports Medicine holds a leading domestic position in China's sports medicine implants and instruments market, ranking fourth overall (6.5% market share) and first among domestic brands in 2024, competing with Arthrex, Smith+Nephew, and Stryker. Key strengths include:
• 9 years of Chinese engineering heritage in sports medicine innovation
• Comprehensive portfolio: 63 products spanning implants, active equipment, consumables, and surgical instruments
• Regulatory compliance: 27 Class III and 25 Class II NMPA certificates; 200+ international registrations across Europe, Southeast Asia, Middle East, and Latin America
• Hospital adoption: Products adopted by over 3,000 hospitals in China, including 1,000+ Class III hospitals
• Patent portfolio: 130+ invention patents granted
• Venture backing: $41.3M raised from investors including Alwin Capital, CCB International, Everest VC, and Hidea Venture Capital
Corporate Timeline
2017 — Founded in Beijing, China, with initial registered capital of RMB63.6 million
2022 — Established Hunan Tianxing subsidiary for R＆D expansion
2023 — Established Suzhou Tianxing subsidiary for manufacturing scale-up
2024 — Recognized as National High-Tech Enterprise and Beijing Municipal Enterprise Technology Center; revenue exceeded RMB300 million
2025 — Cumulative sales surpassed 2 million units; awarded Beijing Science and Technology Progress Award Second Prize
2026 — Completed HKEX IPO (May 5, stock code 1609), raising HKD 8.30 billion; Hong Kong public offering oversubscribed 7,823x; shares opened at HKD 288, up 192% from IPO price
Target Markets ＆ Applications
• Shoulder Surgery: Rotator cuff repair using suture anchors and suture passers
• Knee Reconstruction: ACL/PCL reconstruction with interference screws and suture buttons; meniscus tear repair
• Foot, Ankle, Hip, Elbow, Hand/Wrist: Soft tissue fixation and ligament reconstruction across small and large joints
• Minimally Invasive Arthroscopy: Full arthroscopic tower, shaver systems, and compatible consumables for joint diagnostics and treatment
Contact Information
Global Headquarters
Address: Building 1, A018 and B018, No. 25, Jinghai 2nd Road, Beijing Economic and Technological Development Zone, Beijing, China
Telephone: +86 193 5707 9002
Email: contact@starsportmed.com
Corporate Status
Entity Type: Publicly Listed Company (No Parent Company)
Stock: Hong Kong Stock Exchange: 1609
Website: starsportmed.com
